Variation characteristics and clinical significance of TP53 in patients with myeloid neoplasms

MDS and AML characterized by variations have a poor prognosis in general. However, specifically, differences in prognosis have also been observed in patients with different variants and VAFs. Here, we retrospectively analyzed datasets of patients with MDS, MPN, and AML who underwent targeted DNA sequencing from February 2018 to December 2023, and patients with reportable variations were screened. Demographic data and clinical data were collected, and the relationship between alterations and patient prognosis (AML/MDS) was analyzed using the cBioPortal and Kaplan-Meier Plotter databases. The relationship between the VAFs of variations and prognoses was analyzed using data from the present study. Sixty-two variants of were identified in 58 patients. We mainly identified single mutations (79.31%, 46/58), followed by double (17.24%, 10/58) and triple (3.45%, 2/58) mutations. The variations were mainly enriched in exon4-exon8 of . Missense (72.58%, 45/62) mutations were the main type of variations, followed by splice-site (9.68%, 6/62), nonsense (9.68%, 6/62), frameshift (6.45%, 4/62), and indel (1.61%, 1/62) mutations. In this study, p.Arg175His and p.Arg273His were high-frequency mutations, and and were commonly co-mutated genes in the three types of myeloid neoplasms; However, we reported some new variants in MPN that have not been found in the public database. Moreover, MDS or AML characterized by altered had a shorter OS than patients in the unaltered group (